Tiziana Life Sciences Ltd
TLSA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.09 | -0.12 | 0.05 | 0.18 |
| FCF Yield | -3.32% | -43.70% | -52.50% | -34.35% |
| EV / EBITDA | -2.02 | -1.60 | -0.83 | -0.23 |
| Quality | ||||
| ROIC | -269.73% | -311.64% | -72.72% | -56.40% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.13 | 0.89 | 1.27 | 0.93 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 90.06% | 22.31% | 0.98% | -84.36% |
| Safety | ||||
| Net Debt / EBITDA | 0.22 | 0.05 | 1.16 | 1.55 |
| Interest Coverage | -2,632.33 | -1,798.40 | -2,083.71 | -155.53 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |